Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
TOKYO, February 9, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced its commitment to achieve net zero greenhouse gas (GHG) emissions by 2050...
Read more about Astellas Commits to Achieve Net Zero Greenhouse Gas Emissions by 2050
TOKYO, February 6, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that at a meeting of its Board of Directors, held today, approved changes of its Representative...
Read more about Astellas Announces Change of President and CEO and Management Structure
TOKYO, February 6, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares pursuant...
Read more about Astellas Announces Acquisition of Own Shares and Cancellation of Treasury Stock
TOKYO, January 24, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that Astellas and Sandoz AG (“Sandoz”) have entered into an Asset Purchase Agreement, under which Astellas will transfer the...
Read more about Astellas Transfers MYCAMINE® Product Worldwide
TOKYO, January 20, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on January 19th for the FORTIS Ph1/2 clinical trial evaluating the safety...
Follow us
